Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
approved tags : Als save search
FDA approves QALSODY™ (tofersen) as the first treatment targeting a genetic cause of ALS
Published: 2023-04-25 (Crawled : 00:00) - prnewswire.com
IONS | $41.585 0.08% 0.08% 1.1M
|
Health Technology
|
| O: 0.03%
H: 0.77%
C: -0.39%
fda genetic als treatment
FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS
Published: 2023-04-25 (Crawled : 20:00) - globenewswire.com
IONS | $41.585 0.08% 0.08% 1.1M
|
Health Technology
|
| O: 0.03%
H: 0.77%
C: -0.39%
BIIB | $195.16 -0.83% -0.85% 870K
|
Health Technology
|
| O: -1.35%
H: 3.82%
C: 3.39%
fda genetic als approval treatment grants
NeuroSense Receives Approval in Germany to Enroll Patients in its Phase 2b ALS Trial
Published: 2023-02-08 (Crawled : 14:20) - prnewswire.com
NRSN 4 d | $1.625 6.21% 5.85% 120K
|
|
| O: -0.65%
H: 23.68%
C: 0.0%
enroll als trial approval germany
NeuroSense Receives Regulatory Approval to Commence Patient Enrollment in Italy for its Phase 2b Trial in ALS
Published: 2022-11-16 (Crawled : 15:00) - prnewswire.com
NRSN 4 d | $1.625 6.21% 5.85% 120K
|
|
| O: -5.29%
H: 24.22%
C: 11.84%
als trial approval phase 2b
Amylyx Pharmaceuticals Announces Health Canada Approval of ALBRIOZA™ for the Treatment of ALS
Published: 2022-06-13 (Crawled : 12:00) - biospace.com/
AMLX | $2.015 -2.66% -2.73% 2.1M
|
|
| O: -3.25%
H: 15.66%
C: -0.69%
treatment canada health als approval
Global Generic Injectables Market Research Report 2022: Expiration of Branded Drug Patents & Rising Approvals for Generic Injectable Drugs
Published: 2022-03-15 (Crawled : 23:00) - prnewswire.com
LLY | $746.74 -0.54% 1.01% 2.5M
|
Health Technology
|
| O: 0.87%
H: 0.27%
C: -0.51%
SNY | $45.81 -0.93% -0.94% 1.4M
|
Health Technology
|
| O: 0.82%
H: 0.0%
C: 0.0%
als drug patent research approval report
Catalyst Pharmaceuticals and KYE Pharmaceuticals Announce a Second Favorable Canadian Federal Court Ruling Setting Aside Approval of Ruzurgi®
Published: 2022-03-11 (Crawled : 13:30) - globenewswire.com
CPRX | $15.55 1.04% 1.03% 920K
|
Health Technology
|
| O: 1.55%
H: 0.0%
C: 0.0%
ruzurgi als ide approval approval set
TRACON Pharmaceuticals Announces FDA Approval of Amended ENVASARC Protocol
Published: 2022-03-10 (Crawled : 14:00) - globenewswire.com
TCON | $1.71 -5.0% -5.26% 260K
|
Health Technology
|
| O: 6.1%
H: 0.0%
C: 0.0%
fda als fda approval approval
CMC Materials Announces Stockholder Approval of Merger Agreement with Entegris
Published: 2022-03-03 (Crawled : 15:00) - globenewswire.com
ENTG | $131.0 -0.51% -0.51% 1.2M
|
Electronic Technology
|
| O: 1.11%
H: 0.03%
C: -3.63%
CCMP | $173.69 0.59% 0.0%
|
Electronic Technology
|
| O: 0.5%
H: 0.0%
C: -1.44%
als approval merger agreement merge
Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel™ in Fragile X SyndromeProvides 10-year market exclusivity in EU upon regulatory approval
Published: 2022-02-28 (Crawled : 23:00) - biospace.com/
ZYNE | $1.3 3.08% 860K
|
Health Technology
|
| O: -4.76%
H: 0.0%
C: 0.0%
als europe drug granted approval drug designation orphan drug grant designation zygel
Halo Collective Receives All Approvals for Budega™ Dispensary in North Hollywood, California
Published: 2022-02-25 (Crawled : 23:00) - prnewswire.com
AKAN | $0.105 -7.08% -7.62% 7M
|
| Email alert
Add to watchlist
als california approval
COVID-19 Nucleic Acid Amplification Tests (NAATs) Medical Devices Pipeline Market Report 2021: Analysis by Stage of Development, Territory, Regulatory Path, Estimated Approval Date, Clinical Trials
Published: 2022-02-11 (Crawled : 21:00) - prnewswire.com
GWHP | $0.0001 4000.0% 86K
|
Mining, Quarrying, and Oil and ...
| Email alert
Add to watchlist
PMCB | $2.15 1.9% 1.86% 12K
|
Manufacturing
| Email alert
Add to watchlist
TMO | $554.55 -0.6% 0.0% 1M
|
Health Technology
| Email alert
Add to watchlist
covid-19 als ces trials device trial approval covid clinical trials report test
AMD Receives All Necessary Approvals for Proposed Acquisition of Xilinx
Published: 2022-02-10 (Crawled : 13:30) - globenewswire.com
AMD | $163.49 1.98% 1.94% 55M
|
Electronic Technology
|
| O: -0.69%
H: 2.27%
C: -2.38%
als acquisition ces approval
Futu Holdings' Subsidiary, Futu Singapore Received Multiple Approvals-in-Principle and Exempt Financial Adviser Status Regarding Trading, Clearing, and Investment Advisory in Singapore
Published: 2022-02-10 (Crawled : 06:00) - globenewswire.com
FUTU | $54.76 -3.58% -3.71% 1.2M
|
Technology Services
|
| O: -0.85%
H: 8.7%
C: 1.15%
als approval
Trilogy Metals Announces Approved Program and Budget for the Ambler Access Project
Published: 2022-02-07 (Crawled : 12:00) - prnewswire.com
TMQ | $0.5055 -4.26% -0.51% 160K
|
Non-Energy Minerals
|
| O: 1.37%
H: 2.7%
C: 2.7%
als ces program
Catalyst Pharmaceuticals Reports that the FDA Marketing Approval Previously Granted for Ruzurgi® is No Longer Valid
Published: 2022-02-03 (Crawled : 14:30) - biospace.com/
CPRX | $15.55 1.04% 1.03% 920K
|
Health Technology
|
| O: -1.38%
H: 1.84%
C: -0.88%
ruzurgi fda als granted approval report grant
IMTIS Holdings requests Turkcell Board to Call General Assembly of Shareholders to approve Board Changes and Proposals for Improved Corporate Governance
Published: 2022-02-02 (Crawled : 17:00) - prnewswire.com
BW | $0.9953 -5.21% 2.48% 1.6M
|
Electronic Technology
|
| O: -1.63%
H: 0.0%
C: 0.0%
als cel
Mountain Province Diamonds Announces that Board of Directors Approves Junior Credit Facility Transaction, and Mailing of Materials for Upcoming Special Meeting of Shareholders
Published: 2022-02-01 (Crawled : 01:00) - prnewswire.com
MPVDF | $0.1301 0.71% 52K
|
Non-Energy Minerals
|
| O: 0.87%
H: 0.0%
C: -2.44%
als ces
Inspira Technologies Signs a Strategic Agreement in the U.S. to Target $212 Million for Inspira Over a 7-Year Period, Subject to Regulatory Approvals
Published: 2022-01-31 (Crawled : 14:30) - biospace.com/
IINN | $1.91 -1.04% -1.05% 280K
|
Manufacturing
|
| O: 43.91%
H: 6.95%
C: -5.14%
als 2 million approval
Algernon Pharmaceuticals Files for Clinical Trial and Ethics Approval for Phase 1 DMT Human Stroke Study
Published: 2022-01-19 (Crawled : 12:30) - globenewswire.com
AGNPF | $0.0682 178.69% 300
|
Health Technology
|
| O: 1.33%
H: 1.73%
C: -14.06%
als trial approval stroke phase 1 phase 2 phase 3
Gainers vs Losers
| 58% | 42% |
Top 10 Gainers
WISA 4 | $6.06 246.29% 71.12% 200M
|
Electronic Technology
VIAO | $0.265 -13.96% 35.85% 960K
|
Electronic Technology
JAGX | $0.178 49.83% 33.26% 600M
|
Health Technology
SXTC | $1.68 43.59% 30.36% 34M
|
Health Technology
DYNT | $0.531 43.36% 30.24% 22M
|
Health Technology
KA | $0.4796 41.06% 29.11% 5.3M
|
Manufacturing
PALI | $5.86 40.87% 29.01% 29M
|
Manufacturing
CLNN | $0.319 -3.74% 28.75% 6.3M
|
BSGM | $1.52 38.18% 27.63% 3.3M
|
Health Technology
MCBC | $13.67 37.66% 27.36% 2.2M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.